JP2007514699A5 - - Google Patents

Download PDF

Info

Publication number
JP2007514699A5
JP2007514699A5 JP2006544368A JP2006544368A JP2007514699A5 JP 2007514699 A5 JP2007514699 A5 JP 2007514699A5 JP 2006544368 A JP2006544368 A JP 2006544368A JP 2006544368 A JP2006544368 A JP 2006544368A JP 2007514699 A5 JP2007514699 A5 JP 2007514699A5
Authority
JP
Japan
Prior art keywords
inhibitor
hypusinated
leukemia
ciclopirox
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006544368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007514699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/014439 external-priority patent/WO2005058320A1/en
Publication of JP2007514699A publication Critical patent/JP2007514699A/ja
Publication of JP2007514699A5 publication Critical patent/JP2007514699A5/ja
Pending legal-status Critical Current

Links

JP2006544368A 2003-12-19 2004-12-17 (a)N−{5−[4−(4−メチル−ピペラジノ−メチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリミジン−アミンおよび(b)少なくとも1個のハイプシン化阻害剤を含む組み合わせ物およびその使用 Pending JP2007514699A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53156303P 2003-12-19 2003-12-19
PCT/EP2004/014439 WO2005058320A1 (en) 2003-12-19 2004-12-17 COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF

Publications (2)

Publication Number Publication Date
JP2007514699A JP2007514699A (ja) 2007-06-07
JP2007514699A5 true JP2007514699A5 (enExample) 2008-02-07

Family

ID=34700180

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006544368A Pending JP2007514699A (ja) 2003-12-19 2004-12-17 (a)N−{5−[4−(4−メチル−ピペラジノ−メチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリミジン−アミンおよび(b)少なくとも1個のハイプシン化阻害剤を含む組み合わせ物およびその使用

Country Status (17)

Country Link
US (1) US20080139480A1 (enExample)
EP (1) EP1696917A1 (enExample)
JP (1) JP2007514699A (enExample)
KR (1) KR20060125810A (enExample)
CN (1) CN1889952A (enExample)
AU (2) AU2004298761A1 (enExample)
BR (1) BRPI0417759A (enExample)
CA (1) CA2547196A1 (enExample)
EC (1) ECSP066656A (enExample)
IL (1) IL176070A0 (enExample)
MA (1) MA28240A1 (enExample)
MX (1) MXPA06006925A (enExample)
NO (1) NO20063326L (enExample)
RU (1) RU2006125741A (enExample)
TN (1) TNSN06182A1 (enExample)
WO (1) WO2005058320A1 (enExample)
ZA (1) ZA200603904B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009027473A1 (en) 2007-08-31 2009-03-05 Janssen Pharmaceutica Nv Combinations of imazalil and hydroxypyridones
WO2009036753A2 (de) * 2007-09-20 2009-03-26 Schebo Biotech Ag Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
EP2252147B1 (en) 2008-02-06 2012-12-05 Janssen Pharmaceutica NV Combinations of fludioxonil and pyrion compounds
EP2242365B1 (en) * 2008-02-06 2013-01-16 Janssen Pharmaceutica NV Combinations of pyrimethanil and pyrion compounds
WO2010048712A1 (en) * 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
CN103153309A (zh) * 2010-06-01 2013-06-12 拜欧赛里克斯公司 使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
WO2011153197A1 (en) 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
US8691834B2 (en) 2010-06-10 2014-04-08 Janssen Pharmaceutica Nv Combinations of pyrimethanil and monoterpenes
CN102958366B (zh) 2010-07-01 2015-02-11 詹森药业有限公司 pyrion化合物与聚乙烯亚胺的抗微生物组合
CN103191110A (zh) * 2013-03-28 2013-07-10 中国科学院昆明植物研究所 环吡酮及环吡酮胺在制备防治黑色素瘤的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8528983D0 (en) * 1985-11-25 1986-01-02 Ciba Geigy Ag Use of chelating agents
EP0227593A1 (en) * 1985-11-25 1987-07-01 The Hospital For Sick Children Use of chelating agents
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
ES2331562T3 (es) * 2001-03-23 2010-01-08 Enzon, Inc. Profarmacos de agentes anticancerigenos que emplean acidos aromaticos sustituidos.
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms

Similar Documents

Publication Publication Date Title
JP5579715B2 (ja) cdk阻害剤および抗悪性腫瘍剤を含む治療用組合せ
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
JP2009532438A5 (enExample)
JP2004531549A5 (enExample)
JP2003523325A5 (enExample)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
JP2007514699A5 (enExample)
JP2007511487A5 (enExample)
NO20076323L (no) Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metyl-fenyl}-4-(3-pyridyl)-2-pyrimidinamin og en aromataseinhibitor, anvendelse av kombinasjonen samt farmasøytisk preparat
WO2004030627A2 (en) Synergistic methods and compositions for treating cancer
RU2006136881A (ru) Фармацевтическая композиция, содержащая производное бензодиазепина и ингибитор белка слияния rsv
JP2010532373A5 (enExample)
JP2014525454A5 (enExample)
KR20160043117A (ko) 가속화된 경화반 퇴행을 위한 조성물 및 치료방법
JP2016514141A5 (enExample)
RU2006125741A (ru) Комбинация (а) n-{5-[4-(4-метилпиперазинометил)бензоиламило]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамина и (б) по меньшей мере одного ингибитора гипузинации и ее применение
CN101939001A (zh) 用于治疗卵巢癌的含有紫杉醇的组合
WO2011149110A1 (en) Novel composition for the prevention and/or treatment of thromboembolism
JP2012528824A5 (enExample)
WO2011098799A3 (en) Respiratory disease treatment
JP2006505582A5 (enExample)
EP4545142A3 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
JP2009511450A5 (enExample)
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease